Revenue: As of FY2025 Q1, the actual value is USD 3.269 M, missing the estimate of USD 3.39 M.EPS: As of FY2025 Q1, the actual value is USD -0.004.EBIT: As of FY2025 Q1, the actual value is USD -1.921 M, missing the estimate of USD -1.334 M.<h3>ONM Environmental</h3><ul><li>Revenue: $2,803,000 for the three months ended March 31, 2025, a decrease of 39% compared to the same period in 2024.</li><li>Cost of Goods Sold: 54% of revenue for the three months ended March 31, 2025, an increase of 1% compared to the same period in 2024.</li><li>Operating Income: $956,000 for the three months ended March 31, 2025, compared to $1,798,000 for the same period in 2024.</li></ul><h3>BLEST (Engineering)</h3><ul><li>Revenue: $466,000 for the three months ended March 31, 2025, an increase of 152% compared to the same period in 2024.</li><li>Cost of Revenues: 58% of revenues for the three months ended March 31, 2025, compared to 40% in the same period in 2024.</li><li>Operating Loss: $378,000 for the three months ended March 31, 2025, compared to $445,000 for the same period in 2024.</li></ul><h3>Clyra Medical</h3><ul><li>Revenue: No revenue generated in the three months ended March 31, 2025, or 2024.</li><li>Total Costs and Expenses: $1,315,000 for the three months ended March 31, 2025, including $335,000 in research and development expenses.</li></ul><h3>BETI</h3><ul><li>Revenue: No revenue generated in the three months ended March 31, 2025.</li><li>Total Costs and Expenses: $94,000 for the three months ended March 31, 2025, including $60,000 in research and development expenses.</li></ul><h3>BEST</h3><ul><li>Revenue: No revenue generated in the three months ended March 31, 2025.</li><li>Total Expenses: $58,000 for the three months ended March 31, 2025, primarily related to sales and marketing activities.</li></ul><h3>Consolidated</h3><ul><li>Net Loss: $1,921,000 for the three months ended March 31, 2025, compared to $775,000 for the same period in 2024.</li><li>Operating Cash Flow: Net cash used in operating activities was $1,830,000 for the three months ended March 31, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company aims to increase revenues, generate cash from operations, and secure further investment capital to fund business plans and investments in new technologies.</li><li>Non-Core Business: Clyra Medical is focused on launching products and building infrastructure to support sales activities, while BETI is developing the Cellinity battery technology.</li></ul>

BioLargo, Inc. | 10-Q: FY2025 Q1 Revenue Misses Estimate at USD 3.269 M